Tirzepatide in Ten- to Seventeen-Year-Olds

Youth-onset type 2 diabetes is not adult diabetes in a smaller body. It moves faster, responds worse to the medicines that work in adults, and has very few approved treatments. In a trial of 99 people aged 10 to 17, tirzepatide lowered HbA1c by 2.23% — while the placebo group’s blood sugar went up.^[1]

Why the placebo column matters most

In most diabetes trials the control group holds roughly steady. Here it deteriorated. An HbA1c rise of 0.05% over 30 weeks is small in absolute terms and it is the wrong direction, in children whose diabetes was already inadequately controlled on metformin, basal insulin, or both.

That is what an aggressive disease looks like from inside a control group.

It is also the reason the treatment effect here is so large. The estimated difference between groups was 2.28 percentage points (95% CI −2.87 to −1.69) — part of which is the drug working and part of which is the comparison arm losing ground.

What was measured

Across 39 sites in eight countries, participants aged 10 to under 18 with youth-onset type 2 diabetes were randomized in equal thirds to tirzepatide 5 mg, tirzepatide 10 mg, or placebo, for 30 weeks double-blind. Everyone then received tirzepatide for a further 22 weeks. Average age was 14.7, average starting HbA1c 8.04%, and 61% were girls.

Gastrointestinal effects were the commonest adverse events, all mild to moderate, decreasing over time. No deaths occurred. The authors describe the safety profile as consistent with what has been seen in adults.

What 99 children cannot tell you

The 52-week durability claim needs the same care. The double-blind comparison ran 30 weeks; after that everyone received tirzepatide. So “sustained to 52 weeks” describes people continuing to do well on a drug, with no control group left to compare them against.

• Growth and puberty are not addressed by 30 weeks of data.
• Bone accrual, which happens largely in adolescence, is not measured.
• What happens on stopping is unstudied in this age group, and nobody plans to medicate a ten-year-old indefinitely without knowing.
• The trial was funded by Eli Lilly, which makes tirzepatide.

Where this sits among the pediatric evidence

Three separate questions get conflated in coverage of these drugs in young people, and they have different evidence behind them.

The distinction matters because the third has something the first two do not: a hard clinical endpoint in a condition that is actively damaging the child while the trial runs. Blood sugar in diabetes is not a surrogate for anything — it is the disease.

That makes this the strongest pediatric case in the class, and it is still 99 children over 30 weeks.